Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
The definition of asthma has changed considerably in recent years, to the extent that asthma is no longer considered a single disease but a heterogeneous disorder that includes several phenotypes and, possibly, endotypes. A more detailed analysis of the immunological mechanisms underlying the pathog...
Main Authors: | Diego Bagnasco, Matteo Ferrando, Gilda Varricchi, Francesca Puggioni, Giovanni Passalacqua, Giorgio Walter Canonica |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00135/full |
Similar Items
-
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
by: Diego Bagnasco, et al.
Published: (2018-01-01) -
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
by: Gilda Varricchi, et al.
Published: (2017-01-01) -
Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01) -
IL-5 and IL-5 receptor in asthma
by: Kotsimbos ATC, et al.
Published: (1997-01-01) -
IL-5 and IL-5 receptor in asthma
by: ATC Kotsimbos, et al.
Published: (1997-12-01)